Skip to content

Blog

Category: Immunogenicity

Immunogenicity Testing For Biosimilars

Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing costs while providing patients with…

Read More

Determining Immunogenicity for CAR-T cell Therapies

Chimeric Antigen Receptor (CAR)-T cell therapy is a novel cancer therapy that harnesses and redirects the cytotoxic activity of T cells against cancer cells. CAR-T…

Read More

Challenges for Measuring Immunogenicity of AAV-based Gene Therapies

Gene therapy is a powerful form of treatment that involves introducing genetic material into cells to replace defective genes resulting in the production of an…

Read More

Impact of Pre-Existing Immunogenicity Against AAV on Gene Therapy Trials

The concept of using pre-existing immunogenicity as an exclusion criteria for gene therapy clinical trials is changing. BioAgilytix’s Chief Scientific Officer, Dr. Jim McNally, explores…

Read More

Turning Around a Troubled Study: A Rescue Project Success Story

When you have a program that has stalled or gone off schedule, it is vital to team up with a CRO laboratory that is capable…

Read More

Webinar Sneak Peek: Accelerating Testing of Therapeutics to Neutralize Viral Infections

On May 7, we'll be hosting webinar highlighting the importance of streamlining the time & cost of bioanalytical testing to support therapeutic development for viral…

Read More

Answers to Your Questions on Immunogenicity Testing for Biosimilars: Part 2

BioAgilytix’s Todd Lester answers additional questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.

Read More

Questions on Immunogenicity Testing for Biosimilars Answered: Part 1

BioAgilytix’s Todd Lester answers questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.

Read More

Platform Spotlight: ImmunoCAP to Support Diagnosis of Allergic Reactions Against Biologics

The observation of drug-specific IgE antibodies which may cause anaphylaxis prompts the need to test for these antibodies - but because IgE are 2000-fold less…

Read More

Immunogenicity Assessment Using the Biacore™ T200 SPR System

What are the advantages of using the Biacore™ T200 SPR System for immunogenicity assessments with a tiered approach? Our experts discuss.

Read More